Oppenheimer Initiates Coverage on $ATAI with Outperform Rating, PT $14
Analyst comments: "We view ATAI as leading the psychedelic revolution within neuropsychiatry, which remains an under-appreciated market opportunity given approximately 10 million patients who could benefit